Radioiodinated antibody targeting of the HER-2/neu oncoprotein:: Effects of labeling method on cellular processing and tissue distribution

被引:30
|
作者
Zalutsky, MR
Xu, FJ
Yu, Y
Foulon, CF
Zhao, XG
Slade, SK
Affleck, DJ
Bast, RC
机构
[1] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
[3] Univ Texas, MD Anderson Canc Ctr, Div Med, Houston, TX 77030 USA
关键词
HER-2; breast cancer; ovarian cancer; monoclonal antibody; radioiodination; internalization;
D O I
10.1016/S0969-8051(99)00060-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Monoclonal antibody (MAb) internalization can have a major effect on tumor retention of radiolabel. Two anti HER-2/neu MAbs (TA1 and 520C9) were radioiodinated using the iodogen, N-succinimidyl 5-iodo-3-pyridinecarboxylate (SIPC), and tyramine-cellobiose (TCB) methods. Paired label studies compared internalization and cellular processing of the labeled MAbs by SKOv3 9002-18 ovarian cancer cells in vitro. Intracellular radioiodine activity for 520C9 was up to 2.6 and 3.0 times higher for SIPC and TCB labeling, respectively, compared with iodogen. Likewise, intracellular activity for TAI was up to 2.3 and 2.9 times higher with the SIPC and TCB methods compared with iodogen labeling. Unfortunately, similar advantages in tumor accumulation were not achieved in athymic mice bearing SKOv3 9008-18 ovarian cancer xenografts. NUCL MED BIOL 26;7:781-790, 1999. (C) 1999 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:781 / 790
页数:10
相关论文
共 18 条
  • [1] Radioiodinated antibody targeting of the HER-2/neu oncoprotein
    Xu, FJ
    Yu, YH
    Bae, DS
    Zhao, XG
    Slade, SK
    Boyer, CM
    Bast, RC
    Zalutsky, MR
    NUCLEAR MEDICINE AND BIOLOGY, 1997, 24 (05): : 451 - 459
  • [2] RADIOLABELED ANTIBODY TARGETING OF THE HER-2/NEU ONCOPROTEIN
    DESANTES, K
    SLAMON, D
    ANDERSON, SK
    SHEPARD, M
    FENDLY, B
    MANEVAL, D
    PRESS, O
    CANCER RESEARCH, 1992, 52 (07) : 1916 - 1923
  • [3] Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein
    Sato, S
    Kajiyama, Y
    Sugano, M
    Iwanuma, Y
    Sonoue, H
    Matsumoto, T
    Sasai, K
    Tsurumaru, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (01): : 203 - 211
  • [4] Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours
    Pallud, C
    Guinebretiere, JM
    Guepratte, S
    Hacene, K
    Neumann, R
    Carney, W
    Pichon, MF
    ANTICANCER RESEARCH, 2005, 25 (2B) : 1433 - 1440
  • [5] Prognostic significance of c-erbB-2 (HER-2/neu) oncoprotein in benign and malignant breast tumor tissue
    Simícková, M
    Pecen, L
    Cernoch, M
    Vagunda, V
    Pochmon, D
    Vermousek, I
    Lang, B
    Pacovsky, Z
    JOURNAL OF TUMOR MARKER ONCOLOGY, 1999, 14 (04): : 13 - 22
  • [6] Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro
    Brodowicz, T
    Wiltschke, C
    Budinsky, AC
    Krainer, M
    Steger, GG
    Zielinski, CC
    INTERNATIONAL JOURNAL OF CANCER, 1997, 73 (06) : 875 - 879
  • [7] Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
    Mark Pegram
    Sheree Hsu
    Gail Lewis
    Richard Pietras
    Malgorzata Beryt
    Mark Sliwkowski
    Daniel Coombs
    Deborah Baly
    Fairooz Kabbinavar
    Dennis Slamon
    Oncogene, 1999, 18 : 2241 - 2251
  • [8] Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
    Pegram, M
    Hsu, S
    Lewis, G
    Pietras, R
    Beryt, M
    Sliwkowski, M
    Coombs, D
    Baly, D
    Kabbinavar, F
    Slamon, D
    ONCOGENE, 1999, 18 (13) : 2241 - 2251
  • [9] Development of a measles virus vector targeting breast cancer cells by expression of single chain antibody against HER-2/neu
    Yoneda, M.
    Melani, C.
    Doi, T.
    Sato, H.
    Fujita, K.
    Tsukiyama-Kohara, K.
    Kai, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 82 - 82
  • [10] The cytotoxic effects of the anticancer drugs rViscumin and Paclitaxel are dependent on cellular HER-2 (c-erbB2/neu) levels
    Apel, J
    Abuharbeid, S
    Moeckel, B
    Krohn, M
    Malerczyk, C
    Lentzen, H
    Czubayko, F
    Aigner, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S168 - S168